Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02399072 · ClinicalTrials.gov registry record

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A clinical trial, sponsored by Hoffmann-La Roche.

Terminated
Registry status
202
Enrollment target

NCT02399072 is a clinical trial that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 202 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02399072 was terminated before completion, sponsored by Hoffmann-La Roche.

TERMINATED
Registry status
202 participants
Enrollment target

Study Summary

This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study also will generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling 200 participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 60 months.

Interventions

  • OTHER No intervention

Trial Details

FieldValue
Enrollment Target 202 participants
Start Date 2015-03-30
Est. Completion 2018-02-08

Sponsor

Hoffmann-La Roche

909 total trials

What the Registry Record Tells You About NCT02399072

The ClinicalTrials.gov registry entry for NCT02399072 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.

NCT02399072 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02399072 about?

NCT02399072 is a clinical study titled "A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study also will generate new information on the relationship between genetics and GA progression. This is a glob...

What is the current status of trial NCT02399072?

This trial is currently terminated. The enrollment target is 202 participants. The study started on 2015-03-30. Estimated completion is 2018-02-08.

What interventions are being tested in trial NCT02399072?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT02399072?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.